The need to improve immunogenicity of current influenza vaccines, especially in elderly people, have led to the licensure of two new “implemented vaccines” for people aged ≥65 years: Fluad (MF59-adjuvanted subunit vaccine) and Intanza 15µg (split non-adjuvanted intradermal vaccine). The aim of our study was to compare the immunogenicity of the two implemented vaccines commercially available for the Winter season 2012/13 (A/California/7/09 (H1N1), A/Victoria/361/11 (H3N2) and B/Wisconsin/1/10). A total of 172 elderly (mean age 86 years) chronically ill volunteers living in nursing homes located in Umbria, Italy, were randomly assigned to receive one dose of either Fluad (N. 92) or Intanza (N. 80). Haemagglutination inhibiting (HI) antibody titers were determined in blood samples collected before and 1 month after vaccination. The results obtained showed that both vaccines were able to induce increases in the amount of HI antibodies against all the three vaccine strains, although the three immunogenicity criteria of European Medicine Agency were not always satisfied. Non-inferiority of Intanza was demonstrated for all strains (ratios [Fluad/Intanza] of post-vaccination Geometric Mean Titers were always <1.5 and differences between the seroconversion rates [Fluad-Intanza] were always <10%). In conclusion our data evidenced a comparable immunogenicity in elderly people for the two “implemented vaccines” commercially available for the Winter 2012/13, confirming that both vaccines can be considered a strategy to address the challenge of declining immune responses in the elderly.
Antibody response elicited by 2012/2013 “implemented influenza vaccines”, FLUAD® (Novartis Vaccines & Diagnostics) and INTANZA® 15Mcg (Sanofi Pasteur MSD), in chronically ill institutionalized elderly volunteers
CAMILLONI, Barbara;BASILEO, Michela;IORIO, Anna Maria
2013
Abstract
The need to improve immunogenicity of current influenza vaccines, especially in elderly people, have led to the licensure of two new “implemented vaccines” for people aged ≥65 years: Fluad (MF59-adjuvanted subunit vaccine) and Intanza 15µg (split non-adjuvanted intradermal vaccine). The aim of our study was to compare the immunogenicity of the two implemented vaccines commercially available for the Winter season 2012/13 (A/California/7/09 (H1N1), A/Victoria/361/11 (H3N2) and B/Wisconsin/1/10). A total of 172 elderly (mean age 86 years) chronically ill volunteers living in nursing homes located in Umbria, Italy, were randomly assigned to receive one dose of either Fluad (N. 92) or Intanza (N. 80). Haemagglutination inhibiting (HI) antibody titers were determined in blood samples collected before and 1 month after vaccination. The results obtained showed that both vaccines were able to induce increases in the amount of HI antibodies against all the three vaccine strains, although the three immunogenicity criteria of European Medicine Agency were not always satisfied. Non-inferiority of Intanza was demonstrated for all strains (ratios [Fluad/Intanza] of post-vaccination Geometric Mean Titers were always <1.5 and differences between the seroconversion rates [Fluad-Intanza] were always <10%). In conclusion our data evidenced a comparable immunogenicity in elderly people for the two “implemented vaccines” commercially available for the Winter 2012/13, confirming that both vaccines can be considered a strategy to address the challenge of declining immune responses in the elderly.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
